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Background:  Neurologic events (stroke and transient ischemic attack [TIA]) after transcatheter aortic valve replacement (TAVR) are an 
important problem that appears to be procedure, device, and patient related. Prior studies have been limited by reporting variability, short 
follow-up, and few events. We report a comprehensive analysis of time-related incidence, risk factors, and outcome of neurologic events 
after TAVR from the PARTNER-I randomized trial and continued access registries.
methods:  From 4/2007-2/2012, 2621 patients, age 84±7.2 years, underwent transfemoral (TF; 1521) or transapical (TA; 1100) TAVR in 
the PARTNER-I trial. In this as-treated cohort, neurologic events were identified clinically using a protocol, but without formal pre- and 
post-TAVR neurology oversight, and adjudicated by a Clinical Events Committee. Their occurrence and incidence were estimated non-
parametrically by the Kaplan-Meier estimator and parametrically by a multiphase hazard model. A competing risk model was used to 
determine prevalence of neurological events in the face of mortality from other causes.
results:  Within 30 days of TAVR, 3.3% of patients experienced a stroke (TF 3.8% [95% CI 2.9%-4.8%]; TA 2.7% [95% CI 1.9%-3.8%]; 
P=.09), 85% occurring within 1 week. The instantaneous risk of stroke peaked on day 2, then fell to a low prolonged risk by 1-2 weeks. 
Within 30 days, 0.51% experienced a TIA (TF 0.72% [95% CI 0.39%-1.2%]; TA 0.25% [95% CI 0.11%-0.55%], P>.17). Risk factors for early 
stroke in TA-TAVR included number of post-dilatations and pacing runs, and in TF-TAVR higher peak aortic valve gradient. Risk factors for 
late stroke included atrial fibrillation in TA-TAVR and longer procedure time in TF-TAVR. Patients who experienced a neurologic event had 
higher 1-year mortality than patients who did not (TF 53% after stroke vs 18% and 36% after TIA vs 17%; TA 47% after stroke vs 20% and 
36% after TIA vs 17%).
conclusion:  Post-TAVR neurologic events lead to higher 1-year mortality. Risk is highest in the immediate post-procedural period, 
suggesting that modifications of TAVR and emboli-prevention devices, along with better pharmacologic protection during the procedure, 
may mitigate this risk.
